Document Detail

The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis.
MedLine Citation:
PMID:  16363279     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Prostanoids are used in the treatment of Raynaud's phenomenon and acral perfusion disorders secondary to collagenosis. In subjective terms, intravenous administration of these agents produces success in more than 50% of patients. The therapeutic outcome of clinical administration of alprostadil or iloprost may vary from individual to individual.
PATIENTS AND METHODS: The following variables were analysed in a cross-over study in 27 patients with collagenosis and Raynaud's phenomenon: plasma viscosity and erythrocyte aggregation (rheological variables), partial pressure of oxygen and laser Doppler flowmetry in the finger region, and lymphocyte phenotyping and interleukin (IL) determinations (immunological variables).
RESULTS: Laser Doppler flowmetry revealed significant differences between patients with secondary Raynaud's phenomenon and a control group of 25 healthy subjects. Laser Doppler readings did not change significantly as a result of the treatments. Therapy with iloprost produced a reduction in IL-1beta, L-selectin (CD 62 L) and IL-6.
CONCLUSION: The change in immunological variables due to iloprost may explain the long-term effects of prostaglandins in the treatment of Raynaud's phenomenon. From our results it is not possible to infer any preference for iloprost or alprostadil.
S Drinda; T Neumann; G Pöhlmann; H Vogelsang; G Stein; G Wolf; G Hein
Related Documents :
20538219 - Qi gong exercises and feldenkrais method from the perspective of gestalt concept and hu...
18315759 - Enhancement technologies and the person: christian perspectives.
18461499 - The effects of exercise upon symptoms and quality of life in patients diagnosed with ir...
18614899 - Is there a role for sodium bicarbonate in treating lactic acidosis from shock?
7923879 - In vivo inhibition of human neutrophil collagenase (mmp-8) activity during long-term co...
24369889 - A review of nationwide radioactivity comparisons on gamma-ray spectrometry organized by...
21562819 - Effect of leucine supplementation on indices of muscle damage following drop jumps and ...
3115419 - Faecal blood loss in response to exercise.
9579499 - Changing from isoflurane to desflurane toward the end of anesthesia does not accelerate...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  VASA. Zeitschrift für Gefässkrankheiten     Volume:  34     ISSN:  0301-1526     ISO Abbreviation:  VASA     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-12-20     Completed Date:  2006-01-20     Revised Date:  2012-10-19    
Medline Journal Info:
Nlm Unique ID:  0317051     Medline TA:  Vasa     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  243-9     Citation Subset:  IM    
Division of Rheumatology and Osteology, Department of Clinical Medicine III, Friedrich Schiller University Jena, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Flow Velocity / drug effects
Collagen Diseases / complications,  drug therapy*,  physiopathology*
Cross-Over Studies
Cytokines / immunology
Injections, Intravenous
Middle Aged
Prostaglandins / administration & dosage*
Raynaud Disease / drug therapy*,  etiology,  physiopathology*
Skin / blood supply*,  drug effects*,  immunology
Treatment Outcome
Reg. No./Substance:
0/Cytokines; 0/Prostaglandins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pulsatility index is better than ankle-brachial doppler index for non-invasive detection of critical...
Next Document:  Risk factors for survival in patients with end-stage renal disease undergoing infrainguinal bypass s...